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Abstract:  Yeasts  and  moulds  now  rank  amongst  the  10  most  frequently  isolated  pathogens  in 
febrile patients with an impaired immune system. Fungi are mainly opportunistic pathogens that 
only invade the body if a severely weakened natural defense permits them to do so
facilitating an invasive fungal infection are unavoidable because they are directly connected to the 
underlying diseases as well as to their treatment. 
Modern aggressive treatment modalities jeopardize the defense mechanisms to an extent th
fungi with a low virulence may enter the body.
Introduction: Most of the time, the human species live 
in peaceful coexistence with the microorganisms that 
surround them and only  when the  defense system is 
damaged  or  the  concentration  of pathogens reach an 
exceptionally high density, an infection may emerge. 
Most infections pass by unrecognized but sometimes 
the infecting agents do elicit a response of the body, 
which leads to clinically manifest signs and symptoms, 
a  condition  known  as  infectious  disease.  Bacteria, 
viruses,  parasites,  fungi,  prions,  worms,  helminthes
have  all  been  incriminated  in  infectious  diseases,  of 
which those caused by common viruses are the most 
frequent,  and,  until  a  few  decades  ago,  those  by 
bacteria  the  most  feared.  As  strategies  to  control 
bacterial infections in patients improved, fungi be
the most hazardous pathogens. Yeasts and moulds now 
rank  amongst  the  10  most  frequently  isolated 
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Yeasts  and  moulds  now  rank  amongst  the  10  most  frequently  isolated  pathogens  in 
febrile patients with an impaired immune system. Fungi are mainly opportunistic pathogens that 
only invade the body if a severely weakened natural defense permits them to do so
facilitating an invasive fungal infection are unavoidable because they are directly connected to the 
underlying diseases as well as to their treatment. 
Modern aggressive treatment modalities jeopardize the defense mechanisms to an extent th
fungi with a low virulence may enter the body.
Most of the time, the human species live 
in peaceful coexistence with the microorganisms that 
surround them and only  when the  defense system is 
damaged  or  the  concentration  of pathogens reach an 
exceptionally high density, an infection may emerge. 
ections pass by unrecognized but sometimes 
the infecting agents do elicit a response of the body, 
which leads to clinically manifest signs and symptoms, 
a  condition  known  as  infectious  disease.  Bacteria, 
viruses,  parasites,  fungi,  prions,  worms,  helminthes
have  all  been  incriminated  in  infectious  diseases,  of 
which those caused by common viruses are the most 
frequent,  and,  until  a  few  decades  ago,  those  by 
bacteria  the  most  feared.  As  strategies  to  control 
bacterial infections in patients improved, fungi became 
the most hazardous pathogens. Yeasts and moulds now 
rank  amongst  the  10  most  frequently  isolated 
pathogens  among  patients  in  Intensive  Care  Units. 
Approximately  7  percent  of  all  febrile  episodes  that 
occur during neutropenia can be attributed definite
invasive  fungal  infections. 
fourth leading bloodstream isolate in hospitals in the 
USA, surpassing many historically notorious bacterial 
pathogens. Since the eighties an increased incidence of 
invasive fungal infections in pati
end stage of their underlying disease was observed
Moreover, due to the ubiquitous low autopsy rate their 
incidence  is  probably  underestimated  because  signs 
and symptoms are seldom characteristic, which makes 
that many invasive fungal infections are not detected 
while the patient is alive.
2
Why fungi did evolve to become such formidable 
enemies of seriously ill patients? First of all, it is clear 
that fungi, in spite of their potential 
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Yeasts  and  moulds  now  rank  amongst  the  10  most  frequently  isolated  pathogens  in 
febrile patients with an impaired immune system. Fungi are mainly opportunistic pathogens that 
only invade the body if a severely weakened natural defense permits them to do so. Most factors 
facilitating an invasive fungal infection are unavoidable because they are directly connected to the 
Modern aggressive treatment modalities jeopardize the defense mechanisms to an extent that even 
pathogens  among  patients  in  Intensive  Care  Units. 
Approximately  7  percent  of  all  febrile  episodes  that 
occur during neutropenia can be attributed definitely to 
invasive  fungal  infections.  Candida  has  become  the 
fourth leading bloodstream isolate in hospitals in the 
USA, surpassing many historically notorious bacterial 
pathogens. Since the eighties an increased incidence of 
invasive fungal infections in patients who are not in an 
end stage of their underlying disease was observed.
1
Moreover, due to the ubiquitous low autopsy rate their 
incidence  is  probably  underestimated  because  signs 
and symptoms are seldom characteristic, which makes 
gal infections are not detected 
Why fungi did evolve to become such formidable 
enemies of seriously ill patients? First of all, it is clear 
that fungi, in spite of their potential to make bread rise, Mediterr J Hematol Infect Dis 2011; 3; Open Journal System
to provide us with beer and wine, and to give taste to 
cheese and other food, primary belong to the end of 
biological life. They are active in disposing decaying 
organic material, including human corpses, which will 
eventually  be  dissolved  by  fungi,  the  big  cleansing 
machines  of  the  world.  Signals  of  decay  appear  to 
trigger fungal growth and, once activated, the fungus 
will  not  stop  expanding  just  because  medical 
interventions  aim  to  postpone  a  physiological  death. 
On  the  contrary,  modern  treatment  modalities  may 
even  facilitate  the  growth  of  fungi  through  negative 
interference  with  the  remaining  components  of  the 
immune  system.  Let’s  have  a  closer  look  at  these 
peculiar infective agents, called fungi or mycoses.
Figure 1: The Fungus
Mycology: Fungi are remarkable organisms and they
constitute  a  separate  kingdom  for  purposes  of 
classification.  Fungi  are  eukaryotes;  they  have  a 
membrane  surrounding  their  nucleus,  their  cells  are 
much  larger  than  bacteria  and  their  molecular 
processes closely resemble those of plants and animals. 
However, unlike mammalian cells, fungi almost always 
possess a rigid cell wall composed of chitin products 
that surrounds their plasma membrane (see figure 1). 
A fungus is a vegetative organism and is definitely not 
a  plant  either  because  fungi  do  not  synthesize 
chlorophyll.  It  is  non-motile  life  form  and  its  basic 
structural unit consists of either a chain of cylindrical 
cells (hyphae) or an unicellular form, or both. The most 
common  species  like  Aspergillus and  Candida  are 
found  everywhere  on  earth.  Gardens,  playgrounds, 
houses, hotels, hospitals and even the skin and mucous 
membranes  have  been  identified  as  sources  of  fungi 
that caused life-threatening infections. 
In the course of time more than 69.000 species of 
fungi have been described while it has been estimated 
that the total number of fungal species is of the order of 
1.5  million.  They  range  from  giant  puff-balls 
mushrooms - sometimes edible, often poisonous - to 
moulds and yeasts only visible by microscope. Moulds 
are known to have caused massive economic losses and 
even food shortage when they infected and destroyed 
food crops disguised as mildew and rust. Since only a 
limited number of fungi are regular causes of human 
pathology,  the  number  of  seemingly  obscure  names 
and  terms  that  appear  in  the  literature  appear  to  be 
unnecessarily huge. Furthermore, more than one word 
is every so often used to describe one and the same 
thing.  Partly  as  a  result  of  the  purportedly  complex 
mycological  terminology,  clinicians  feel seldom 
tempted  to  extend  their  field  of  interest  to  detailed 
study  of  fungal  pathogens,  leaving  mycology  to 
laboratory  scientists.  However,  if  a  clinician  would 
only take a few minutes, he would be paid back with an 
insight in the mechanisms that make fungi what they 
are,  a  danger  to  very  vulnerable  patients  after  a 
sophisticated  medical  intervention.  Indeed,  very  few 
mycological  terms  need  to  be  captured  in  order  to 
understand the principles of diagnosis and management 
of mycoses. Just a handful of definitions clarifies the 
ratio behind the human observations and deliberations 
that form the basis of fungal classification. 
Fungi,  like  all  living  things,  are  recognized  and 
identified on the basis of their shapes, structures and 
their  behavioral  properties.  Fungi  that  exist 
predominantly in the form of independent single cells 
are usually called yeasts while those based on hyphal 
threads are called moulds (i.e. hyphal fungi). Hyphae 
and yeast are nearly always microscopic cell forms. A 
complex of hyphal strands, hyphal branches and any 
associated  spore-bearing  structure  is  known  as  a
mycelium. Vegetative growth of both yeast and hyphae 
occurs  by  means  of  mitotic,  asexual  cell  division, 
typically  outgrowth  of  a  daughter-burst  from  an 
existing  fungal  cell.  Most  fungi  are  also  capable  of 
meiotic, sexual reproduction. Matings may occur not 
only  between  two  different  fungal  strains,  but  even 
between different cell units within a hypha or between 
mother  and  daughter  yeast  cells;  instances  of  fungal 
parthenogenesis are also known. The result of meiosis 
in  fungi  is  the  formation  of  a  sexual  spore.  Fungal 
species  and  strains  that  are  incapable  of  sexual 
reproduction  are  called  deuteromycetes o 
hyphomycetes, previously defined as fungi imperfecti. 
A  cell  unit  within  a  fungal  hypha  is  segregated, 
although not fully, from its neighbor by a cross-wall or 
septum. The hyphae of zygomycetes have no or only 
very  few  septa.  Some  species  amongst  the 
zygomycetes shed large collections of asexual spores 
inside a rounded sac, a sporangium, and these spores 
are  known  as  sporangiospores.  A  spore  that  is  not 
surrounded by a sporangium is nowadays referred to as 
a  conidium.  Conidia  are  produced  on  or  in  a 
conidiophore that can range from an undifferentiated 
cell membrane
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-mannoproteins
-ß-glucan
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Figure 2: Classification of Fungi
hyphal  cell to  a tissue  complex  visible  to  the  naked 
eye. Most yeasts vegetate by a budding process, 
thereby  forming  a  blastospore.  For  practical  reasons 
practioners  like  to  lump  mycoses  of  similar  origin 
under single headings. One of the broadest collective 
mycosis names so far invented is phaeohyphomycosis, 
which  refers  to  any  infection  caused  by  a  darkly 
pigmented  (dematiaceous)  mould.  Its  antonym, 
hyalohyphomycosis,  has  become  popular  to  describe 
any  infection  caused  by  a  colourless  mould. 
Dermatomycosis refers to any type of fungal infection 
involving  the  skin,  while  the  term  disseminated 
mycosis  describes  a  fungal  infection  that  spreads  to 
involve at least two deep organs and/or the skin. Some 
fungal  pathogens  need  to  change  their  cell  shape  to 
allow  invasion:  such  dimorphic pathogens  usually 
switch from a mould form in their natural environment 
to a budding, round-celled form in tissue. Blastomyces 
dermatitidis,  Histoplasma  capsulatum, 
Paracoccidioides brasiliensis, and Sporotrix schenckii
are  the  best-known  representatives  of  the  dimorphic 
manifestation.  Other  less  common  fungal  pathogens 
behave  similarly  and  many  fungi  display  subtle 
morphological  differences  between  forms  found  in 
tissues  and  shapes  encountered  in  cultures. 
Coccidioides immitis converts from a mould form in 
the  environment  to  a  unicellular  spherule  containing 
sporangia in infected tissue.
3
A simplified, schematic classification of the most 
relevant pathogenic fungi is provided in figure 2.
Pathophysiology of fungal infections: Only a few of 
the  fungi  pathogenic  for  humans  are  sufficiently 
virulent  to  infect  a  healthy  host.  Most  are  relativel 
harmless  unless  they  encounter  an 
immunocompromised  patient,  in  whom  a  weakened 
defence  system  permits  them  to  invade  the  body. 
Under  normal  circumstances,  the  intact  epithelial 
surfaces  of  the  gastrointestinal  tract  will  prohibit 
invasion  by  micro-organisms  and  the  mucociliary 
barrier  of  the  respiratory  tract  prevents aspiration  of 
fungal  cells  and  spores,  while,  in  contrast,  dead  or 
damaged tissue  may turn  into a breeding ground for 
infection. For these reasons invasive fungal infections
have to be ranked amongst the typically opportunistic 
infections. Mediterr J Hematol Infect Dis 2011; 3; Open Journal System
Table 1. Factors promoting invasive fungal infections
Recently  it  has  been  hypothesized  that  the 
susceptibility  to  invasive  fungal  infections  is 
influenced  by  genetic  variation  within  key  innate  or 
adaptive  immune  response  genes  that  may  lead  to  a 
failure  in  the  IL-10  production,  Toll-like  receptor 
polymorphism, plasminogen gene polymorphism, etc.
4,5 These data are very intriguing but for the time being 
severe  damage  to  one  or  more  components  of  the 
immune systems appears to be the most important risk 
factor. As a consequence of treatment-related injury of 
all natural defense systems, invasive fungal infections 
will  occur  in  patients  who  are  treated  for  a 
hematological malignancy. See table 1. High doses of 
chemotherapeutic  agents  not  only  cause  neutropenia, 
they also inflict serious damage to the mucosal barrier, 
resulting  in  impaired  production  of  saliva,  secretory 
IgA, mucus and gastric acid, malabsorption, as well as 
decreased  peristalsis.
6 Debilitating  mucosal  damage 
and  the  widespread  introduction  of  central  venous 
catheters disrupt the integument of patients. Of course, 
neutropenia remains  a  crucial  factor  that 
predisposes for fungal infections but prolonged use of 
even  moderate  doses  of  corticosteroids  is  equally 
detrimental  through  both  impairment  of  the  T-cell 
function and alteration of the glucose metabolism.
7,8 In 
case  of  coincidence  of  these  factors  any  potential 
pathogen  that  has  invaded  damaged  tissue  may  gain 
easy access to the body and, subsequently, disseminate 
rapidly.  A  recent  study  highlights  that  even  patients 
with  hematological  malignancies,  undergoing  a 
nonmyeloablative  allogeneic  "minitransplants"  to 
reduce  transplant-related  toxicity,  are  at  high  risk  of 
contracting an invasive fungal infection.
9 Cytotoxic T-
cells as well as the immunosuppressive agents used to 
control graft-versus-host disease may damage both the 
mucosal barriers and the cellular immunity. Therefore, 
the high incidence of invasive fungal infections in bone 
marrow  transplant  recipients  relative  to  those  who 
received  conventional  cytoreductive  chemotherapy  is 
not a surprising finding. Over the last decennium the 
number of bone marrow transplantation procedures has 
tripled  in  the  western  world,  but  the  position  of 
allogeneic transplantation in the cutting edge of prime 
bringers  of invasive fungal infections in  critically  ill 
patients is at risk. With the growing use of powerful 
immunosuppressive purine analogues, fludarabine, and 
cladibrine, as well as employment of anti-T and anti-B 
cell  antibodies  in  the  conventional  management  of 
lymphoreticular and other hematological malignancies, 
the  number  of  patients  at  risk  will  rise  to  similar 
levels.
10 In  addition,  improved  supportive  care  has 
fostered  the  application  of  more  intensive 
chemotherapeutic  regimens for  malignant  diseases to 
elderly  individuals  and  patients  with  pre-existing 
immunocompromising  diseases  such  as  diabetes 
mellitus  and  chronic  obstructive  pulmonary  disease. 
Where the hematological malignancies have served as 
a  role  model  in  the  recognition  of  invasive  fungal 
infections,  other  diseases,  both  malignant  and  non-
malignant,  that  are  associated  with  intrinsic  or 
treatment-related  immunodeficiencies  followed  suit.
11
In  these  populations  the  incidence  of  invasive 
opportunistic  nosocomial  infections  has  more  than 
doubled over the last decades, because of advances in 
cytotoxic  therapy,  improved  treatment  of  bacterial 
infections, the arrival of AIDS, and, most of all, the 
introduction  of  modern,  very  potent 
immunosuppressive  agents.
10,11 In  addition  to  the 
significant  contribution  of  fungal  infections  to  the 
morbidity and mortality in immunosuppressed patients, 
an estimated 15 percent of the world’s population is 
infected with superficial dermatophyte fungi. There is 
Granulocytopenia
Depressed cellular immunity
-viral infections, e.g. cytomegalovirus
- a.o. corticosteroids, cyclosporin, antithymocyteglobulin, total nodal and total body irradiation
-cytotoxic drugs (cyclophosphamide), purine antagonists
Mucosal barrier injury
Poor hygiene
Genetic predisposition
Use of antibacterials, manipulation of a patient’s microbiological flora
Increasing age of patients with co-morbidity
Use of H2 receptor antagonists
Central venous lines with or without hyperalimentation
Recent gastrointestinal surgery
Neonatal intensive care – low gestational age, low Apgar score, length of stay, intubationMediterr J Hematol Infect Dis 2011; 3; Open Journal System
even an increase in the frequency of this type of fungal 
infections  due  to  life-style  changes  such  as  more 
intense  use  of  swimming  pools and  health  spas  and 
crowding  conditions  in  nursing  homes,  schools  and 
prisons.
Virtually all human fungal infections originate from 
the environment through skin contact with or without 
trauma, or via inhalation or ingestion of fungal spores. 
Candida, the prototype of a colonizing fungus that may 
stay unnoticed on the surfaces of a body has become 
the  most  common  genus  of  fungal  pathogens  and 
remains  very  menacing.  Nowadays  candidemia  has 
become  a  well  recognized  threat  in  hematological 
patients with chemotherapy-induced granulocytopenia, 
notably  in  those  with  concurrent  severe  mucosal 
damage and when venous access devices are in  use. 
Candida species are a normal part of the microflora of 
the  oropharynx  and  the  gut  which  explains  why 
alterations in the equilibrium between the indigenous 
organisms by the use of broad-spectrum antibacterials 
can lead to overgrowth of Candida species. The fact 
that  the  gut  is  a  major  source  of  disseminated 
candidosis  is  increasingly  acknowledged.
6,  12 
Gastrointestinal colonization is recognized as the most 
important  risk  factor  for  candidemia,  perhaps  with 
exception  of  infections  by  Candida parapsilosis,  an 
organism that is commonly found on the skin and has 
been identified as one of the leading causes of venous 
catheter-related fungal infections. Candidemia tends to 
develop rather early during the  treatment course and 
only 10 percent of the infections emerge outside the 
hospital. The incidence of catheter-associated fungemia 
varies from 1-16 percent and depends on the presence 
of the recognized risk factors. Whilst the incidence of 
Candida infections declined since the  late  1970s, an 
increase  in  the  rate  of  pulmonary  aspergillosis  was 
observed.
2,13 Some even reported an incidence as high 
as  40  percent  amongst  recipients  of  sibling  marrow. 
Aspergillus species, notably Aspergillus fumigatus, are 
undoubtedly prominent and deadly fungal pathogens. 
Aspergillus species  are  airborne  pathogens  that  pass 
through  the  nose,  may  penetrate  into  the  paranasal 
sinuses  and  will  eventually  land  in the  lower 
respiratory  system  that  constitutes  the  major  port-
d’entrée.  The  inevitable  risk  factors,  such  as  graft-
versus-host disease, high dose corticosteroid use, and 
recurrent prolonged neutropenia explain the increasing 
rate of pulmonary aspergillosis as well as the bimodal 
time distribution curve of the development of invasive 
aspergillosis amongst recipients of allogeneic stem cell 
transplants.
14,15 Approximately 40 percent of the cases 
of aspergillosis will surface within a few weeks after 
transplantation,  i.e.  before  engraftment.  The  second 
peak of incidence occurs after 100 days or more when 
typically  graft-versus-host  disease  necessitates  the 
employment  of  high  doses  of  corticosteroids  and 
ganciclovir treatment  of cytomegalovirus  reactivation 
reintroduces neutropenia.
15 After marrow engraftment 
and mucosa healing, the incidence of fungal infections 
diminishes  accordingly  until  the  cell-mediated 
immunity has fully recovered. This may require quite 
some time, especially in case of chronic graft-versus-
host disease.
During  the  last  decades  an  obvious  change  in 
pathogens  has  occurred.  More  aggressive  treatment 
modalities can jeopardize the defense mechanisms to 
an extent that even fungi with a low intrinsic virulence 
enter the body to cause serious disease. Organisms that 
were previously considered harmless commensals have 
been  held  accountable  for  serious  invasive  fungal 
disease. Non- Aspergillus moulds  like  Zygomycetes 
can generate a clinical picture indistinguishable from 
Aspergillus.
16 Fusarium,  a soil  fungus, can  enter the 
body  through  the  respiratory  system  or  via  severe 
onychomycosis  but  has  also  been  connected  with 
venous  access  devices,  its  prevalence  being  clearly 
higher  in  patients who  carry a  central  venous line.
17
Scedosporium,  another  emerging  pathogen,  is  being 
increasingly isolated from patients with a persistently 
impaired  cellular  immunity  in  combination  with  a 
protracted granulocytopenia.
18,19 In 1984, 80 percent of 
candida bloodstream infections were due to Candida 
albicans,  whereas  in the  1990's  non-albicans  species 
have  become  responsible  for  at  least  half  of  these 
infections  in  patients  treated  for  hematological 
malignancies.
20 Both  the  decrease  in  the  number  of 
Candida infections and the shift towards non-Candida 
albicans strains is presumably linked with the use of 
fluconazole for prophylaxis. Obviously, suppression of 
the  predominant  and  virulent  Candida  albicans
subpopulation  created  space  for  less  susceptible 
organisms. 
Diseases  caused  by  invasive  fungal infections:  A 
comprehensive  list  of  all  fungi  that  have  been 
incriminated  as  opportunistic  human  pathogens  may 
well exceed 400 species, even if the list is restricted 
solely to those species for which evidence of infection 
is  available.  Many  of  the  species  listed  would  have 
been  encountered  clinically  on  very  few  occasions 
indeed –often only once or twice- so that fewer than 
100  fungal  species  approach  the  status  of  regular 
human  pathogens.  The  characteristics  of  all  invasive 
mycoses that have been reported in the literature during 
the last 25 years are summarized in table 2. Invasive 
fungal infections can be divided in two distinct groups: 
The endemic or dimorphic mycoses that are caused by 
true  pathogenic  fungi  as  compared  with  the 
opportunistic  mould  and yeast  infections  that  are 
saprophytes,  which  only  will  invade  anMediterr J Hematol Infect Dis 2011; 3; Open Journal System
Table 2. Invasive fungal infections; pathogens and characteristics of disease.
OPPORTUNISTIC PATHOGENS
Disease type Causative agent Clinical signs and symptoms
Candidiasis Candida spp
Acute  disseminated:  fever,  chills,  polymyalgia,  polyarthralgia,  not  tender 
pinkish skin lesions, retinal exudates.
Chronic: complaints of the organ involved.
Aspergillosis Aspergillus spp
Unremitting  fever  and  pulmonary  infiltrates  during  antibiotic  therapy.  Chest 
pain, pleural rub, pleural effusion, hemoptysis. Halo and air crescent sign on 
chest radiograph and CT scan.
Clinical and radiologic sinusitis.
Cryptococcosis Cryptococcus neoformans Flu-like symptoms; skin lesions, headache without meningismus.
Zygomycosis
Rhizopus spp
Like  aspergillosis,  more  outspoken  rhino-cerebral  form  with  serosanguinous 
nasal discharge. Absidia spp
Mucor spp
Others
Malassezia furfur Often catheter-associated; pneumonia
Skin and lung lesions
Often positive bloodcultures. Skin lesions, severe myalgia. Abscess formation 
with symptoms depending on organ involved.
Like aspergillosis; wound infections.
Trichosporon spp
Fusarium spp
Pseudallescheria boydii
Scedosporium spp
Alternaria spp
ENDEMIC PATHOGENS
Disease type Causative agent Clinical signs and symptoms
Blastomyscosis Blastomyces dermatitidis
Ulcerative lesions; skin, urogenital tract
Central nervous system
Histoplasmosis Histoplasma capsulatum
Pulmonary infiltrates; mucocutaneous ulcers
Hepatosplenomegaly
Coccidioidomycosis Coccidioidis immitis Pulmonary infection. Dissemination with osteomyelitis, arthritis, meningitis.
Para-coccidioidomycosis   Paracoccidioidis brasiliensis Pulmonary infection. Dissemination to skin, mucosa  and lymphnodes.
Penicilliosis Penicillium marneffei Skin and subcutaneous laesions, lung, lymphadenitis, splenomegaly.
immunocompromised  host.  Histoplasmosis, 
coccidioidomycosis,  blastomycosis  and 
paracoccidioidomycosis are referred to as the endemic 
mycoses  because  they  used  to  be  geographically 
confined to certain regions on the American continent. 
Similarly, Penicillium marneffei was typically seen in 
Southeast Asia. However, as a result of increased travel 
activities  these  infections  can  now  occur  anywhere. 
Candidiasis  and  aspergillosis  are  the  most  common 
diseases caused by opportunistic fungi.
21,22
Invasive  Candida  infections  originate  most 
frequently from endogenous reservoirs in patients with 
lowered  host  defense  but  exogenous  infections  in 
hospitalized patients are frequently transmitted via the 
hands  of  health  care  workers.  Deep-seated  invasive 
infections  tend  to  occur  principally  in  two  different 
patient  populations:  granulocytopenic  patients  with  a 
hematologic  malignancy  and,  alternatively,  intensive 
care  patients  after  multiple  abdominal  surgery,  with 
central venous lines, renal failure and treatment with 
broad  spectrum  antibiotics.
7 Discrimination  between 
colonization  and  invasive  Candida  infection  can  be 
very  vexing  in  the  febrile  unstable  intensive  care 
patient  who  shows  negative  blood  cultures  but  has 
Candida cultured  from  non-sterile  body  sites. 
Secondary bloodstream infections, which evolve from 
other  infectious  foci  such  as  wounds,  carry  a  much 
higher  mortality  than  do  primary,  catheter-related 
infections.
23,  24.  Some  patients  present  with  sudden 
onset  of  fever,  tachycardia,  tachypnea,  occasionally 
accompanied  by  chills  and  hypotension  during 
treatment  with  broad  spectrum  antibacterials. 
Additional clinical clues that should lead to a suspicion 
of Candida infection include unexplained polymyalgia, 
polyathralgia,  and  azotemia.  In  about  10  percent  of 
patients  with  acute disseminated  candidiasis 
characteristic pinkish-purple, not tender subcutaneous 
nodules  may  arise  anywhere  on  the  body.  Biopsy 
specimens  should  be  cultured  and,  additionally, 
meticulously screened histologically at multiple levels 
in  an  attempt  to  establish  a  final  diagnosis.  Clinical 
symptoms  of  Candida ophthalmitis  seldom  occur  in Mediterr J Hematol Infect Dis 2011; 3; Open Journal System
neutropenic patients since the lesions and complaints 
are  the  result  of  an  inflammatory  response  of 
granulocytes. Other patients show an insidious onset of 
their  candidemia,  in some  cases  due  to  concurrent 
corticosteroids that  suppress fever;  they  feel  initially 
relatively well until the infection progresses and organ 
failure becomes evident. Disseminated candidiasis may 
mimic  a  single  organ  infection  but  in  most  cases  a 
number  of  organs  are  affected.  Primary  Candida
pneumonia  is  regarded  as  exceptional,  whereas  the 
frequency of pulmonary involvement in disseminated 
infection may be as high 50 percent. The attributable 
mortality  from  candidemia  ranges  from  about  40 
percent in patients with candidemia alone to over 90 
percent for those who have acute tissue invasion with 
or without fungemia. Many patients die within the first 
48 hours after establishing the diagnosis.
25 There does 
not seem to exist a substantial difference in outcome 
between severely ill neutropenic and non-neutropenic 
patients. Within the category of patients who had been 
treated  for  a  malignancy,  however,  a  return  of  the 
granulocytes is an important prognostic feature.
The most common initial presentation of invasive 
aspergillosis  is  unremitting  fever  accompanied  by 
development of lung infiltrates despite broad-spectrum 
antibacterial treatment, typically after the second week 
of chemotherapy-induced neutropenia or highly dosed 
corticosteroids.
26 In approximately 90 percent of cases 
the lungs are the portal of entry, with nasal sinuses and 
the  skin  accounting  for  the  remainder  of  cases. 
Clinicians  should  suspect  the  diagnosis  in  a  patient 
with pleuritic pain, hemoptysis, localized wheezing and 
rubbing, or radiographic evidence of a pleural effusion 
or localized pulmonary infiltrates. The symptoms are 
due to fungal invasion causing extensive necrosis and 
occlusion of small blood vessels and resemble those of 
a  pulmonary  infarction.  A  distinct  halo  of  low 
attenuation surrounding the lesions and a so-called air 
crescent sign  on  a  chest  radiograph  or computerized 
tomography are generally regarded as characteristic of 
aspergillosis.
26 The  majority  of  cases  of  invasive 
aspergillosis  are  treated  on  a  presumptive  diagnosis 
because  invasive  diagnostic  procedures  are  either 
unavailable,  unreliable  or  precluded  by  concomitant 
thrombocytopenia.  For  practical  purposes  it  is 
generally accepted that isolation of Aspergillus species 
from clinical specimens such as bronchial washings in
the  neutropenic  patient  connotes  either  invasive 
infection or a high risk of developing invasive disease 
shortly. It has to be underscored that it is important that 
even  after  start  of  systemic  antifungal  therapy,  a 
definite  diagnosis  remains  to  be  pursued  and  that 
infections  by  other  pathogens  such  as  Actinomyces, 
Mycobacteria,  Nocardia,  and  other  rare  fungi  are 
excluded  as  much  as  possible.  A  questionable 
diagnosis  will  keep  nurturing  uncertainty  among 
attending  physicians  about  the  optimal  therapeutic 
strategy,  particularly  if  the  patient  is  not  responding 
optimally  or  if  serious  adverse  events  arise.  A  final 
diagnosis will also have substantial prognostic value as 
well as implications for long-term treatment. Whereas 
the  response  rate  of  patients  with  persisting 
unexplained fever to systemically active antifungals is 
about 80 percent if neutropenia resolves, the successful 
outcome of documented invasive fungal infection may, 
even  under  optimal  circumstances,  not  exceed  20 
percent.
27,28 This  figure  is  greatly  influenced  by  the 
state of the underlying disease and possible recovery of 
the granulocytes and cellular immunity.
29
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